Leavell Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Leavell Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47M	Buy	26,916 +2,350	+10%	+$124K	0.05%	270
2026 Q1	$1.17M	Buy	24,566 +1,000	+4%	+$52.7K	0.05%	285
2025 Q4	$1.24M	Buy	23,566 +400	+2%	+$24K	0.05%	272
2025 Q3	$1.5M	Buy	23,166 +5,389	+30%	+$309K	0.06%	253
2025 Q2	$865K	Buy	17,777 +7,777	+78%	+$301K	0.04%	323
2025 Q1	$340K	Buy	+10,000	New	+$424K	0.02%	450
2024 Q4	–	Sell	-5,700	Closed	-$268K	–	541
2024 Q3	$268K	Sell	5,700 -6,950	-55%	-$353K	0.01%	481
2024 Q2	$683K	Buy	12,650 +2,150	+20%	+$124K	0.04%	316
2024 Q1	$716K	Hold	10,500	–	–	0.04%	305
2023 Q4	$657K	Buy	10,500 +4,400	+72%	+$243K	0.04%	300
2023 Q3	$277K	Buy	+6,100	New	+$315K	0.02%	402

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Leavell Investment Management's CRSP Position: Q2 2026 in Review

Leavell Investment Management increased its CRISPR Therapeutics (CRSP) stake by 9.6% in Q2 2026, buying an estimated $124K and bringing the position to 26,916 shares worth $1.47M. The position accounts for 0.05% of the portfolio, ranked #270.

Leavell Investment Management first reported a position in CRSP in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.5M in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Leavell Investment Management held 26,916 shares of CRISPR Therapeutics worth $1.47M as of Q2 2026.
Leavell Investment Management bought 2,350 CRISPR Therapeutics shares in Q2 2026, an estimated $124K.
CRISPR Therapeutics made up 0.05% of Leavell Investment Management's portfolio in Q2 2026, its #270 holding.
Leavell Investment Management first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 11 quarters since.
Leavell Investment Management's CRISPR Therapeutics position peaked at $1.5M in Q3 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Leavell Investment Management's 13F filing for Q2 2026, filed 21 Jul 2026.